I read the article.

It states that "The problem is that the studies with BG-12 covered a two-year period, but no longer periods," Schulz said, and he believes it may take prolonged treatment with the drug for PML to surface."

It also states that "The ingredient, dimethyl fumarate, is used in a drug called Fumaderm that was approved in Germany in 1994 to treat the skin condition psoriasis. It is also in a different but closely related medication called Tecfidera, which was just approved by the U.S. Food and Drug Administration in March for the treatment of multiple sclerosis (MS). It is known as a fumaric acid ester, which is commonly used as a food additive and has been used to treat psoriasis in Germany for 30 years."

It's going to take some time for any cases of PML to surface for patients who take Tecfidera. A two-year study just isn't, in my humble opinion, long enough to make an educated decision.

Each patient has to make their own decision and decide whether or not the risk versus the gain is something they're willing to take. There are no "wrong" decisions here.....just individual ones.